Integra LifeSciences Holdings Corporation · NASDAQ:IART

Integra LifeSciences — FY2021 Earnings Presentation

26 slides from Integra LifeSciences's earnings presentation, Feb 23, 2022

  1. Slide 1: Q4 & FY 2021 Earnings Presentation

    Q4 & FY 2021 EARNINGS PRESENTATION FEB 23, 2022

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of hist

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted fre

  4. Slide 4: Jan de Witte, President & CEO

    INTEGRA. SMe sane wirre LIMIT UNCERTAINTY PRESIDENT & CEO

  5. Slide 5: Operational Overview

    OPERATIONAL OVERVIEW GLENN COLEMAN EVP & COO

  6. Slide 6: Significant Progress Achieved in 2021

    Significant Progress Achieved in 2021 Major Accomplishments and Milestones  Divested orthopedics business and acquired ACell to expand regenerative  Launched CereLink® ICP monitor​ in Europe and the U.S.  Held investor day outlining profitable growth strategy tissue portfolio and long-term financ

  7. Slide 7: 2021 FY Financial Highlights and 2022 Outlook

    2021 FY Financial Highlights and 2022 Outlook Revenue recovery & organic growth +14.2% vs. 2020, +4.6% vs. 2019 Adj. EBITDA margin expansion vs. 2020 +160bps 2021 FY Adj. EPS growth vs. 2020 +30% Record Operating Cash Flow $312M and >90% FCF Conversion Drive top line growth in persistent COVID envir

  8. Slide 8: Q4 & FY 2021 Financial Performance

    Q4 & FY 2021 FINANCIAL PERFORMANCE Carrie Anderson EVP & CFO

  9. Slide 9: 2021 Q4 and FY Total Revenue

    2021 Q4 and FY Total Revenue ($M) Q4 2021 Full Year 2021 Reported 4.3% Reported 12.4% Organic 8.3% Organic 14.2% $1,6 00.0 $1,542.4 1 $42 0.0 1 $405.5 $1,5 00.0 $41 0.0 $1,4 00.0 $1,371.9 $388.6 $40 0.0 $1,3 00.0 0.5 $39 0.0 0.5 $1,2 00.0 $38 0.0 $1,1 00.0 $37 0.0 $36 0.0 0 $1,0 00.0 0 4Q'20 4Q'21 F

  10. Slide 10: Codman Specialty Surgical Q4 Revenue

    Codman Specialty Surgical Q4 Revenue Revenues Q4’21 Q4’20 Growth Reported $270.7M $254.3M 6.4% Q4 2021 Organic1 $271.2M $248.8M 9.0% Revenue Composition Q4 2021 Growth and Performance Drivers2 Instruments Neurosurgery Instruments International 21.7% 8.9% 9.2% + Double Digits • Neurosurgery – Low dou

  11. Slide 11: Tissue Technologies Q4 Revenue

    Tissue Technologies Q4 Revenue Revenues Q4’21 Q4’20 Growth Reported1 $134.9M $134.4M 0.4% Q4 2021 Organic2 $118.0M $110.6M 6.7% Revenue Composition Q4 2021 Growth and Performance Drivers3 Private Wound Reconstruction Private Label International Label 24.8% 3.8% 14.8% + Double Digits • Wound Reconstr

  12. Slide 12: 2021 Q4 and FY Financial Results

    2021 Q4 and FY Financial Results ($M except per share data) Q4 2021 Full-Year 2021 Adj. Gross Profit Adj. EBITDA Adj. EPS Adj. Gross Profit Adj. EBITDA Adj. EPS (140bps) Margin (40bps) Margin Flat (30bps) Margin +160bps Margin +29.8% $265.2 $271.1 $102.7 $105.4 $1,043.5 $400.7 $3.18 $0.84 $0.84 $30

  13. Slide 13: Balance Sheet and Cash Flow Performance

    Balance Sheet and Cash Flow Performance Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%) Summary Balance Sheet ($M) 12/31/20 12/31/21 FCF Capex $312.4 350 Cash and Cash Equivalents $470 $513 $48.0 300 Total Debt $1,663 $1,563 250 $203.8 $80.3 Net Debt $1,193 $1,050 90 200 80 $8.4 $

  14. Slide 14: Q1 2022 and FY 2022 Outlook

    Q1 2022 and FY 2022 Outlook Q1 Reported Revenue Guidance Bridge ($M) Q1 2022 • Revenue: $357M-$365M 0% - 2.5% ~Flat ~($4) $360 $357 - $365 • Reported Growth -1% to +1.5% • Organic Growth 0% to +2.5% • Adj EPS $0.67 - $0.71 2022 Reported Revenue Guidance Bridge ($M) FY 2022 3.5% - 5% ~($5) ~($13) • R

  15. Slide 15: Growth Acceleration and 2022 Focus

    GROWTH ACCELERATION AND 2022 FOCUS JAN DE WITTE PRESIDENT & CEO

  16. Slide 16: Poised for Accelerated Growth

    Poised for Accelerated Growth Organic Revenue Growth… …Bolstered by Inorganic Opportunities 5% - 7% Long-term Target Synergistic M&A Adjacencies & International 4% - 5% International Expansion • Digital Solutions New Product Introductions CereLink • Aurora • ACell • NeuraGen® 3D• SurgiMend Core Orga

  17. Slide 17: Growth Catalysts and 2022 Focus

    Growth Catalysts and 2022 Focus NEAR-TO MID-TERM GROWTH CATALYSTS AREAS OF FOCUS FOR 2022 • International opportunities led by Japan and China • Step up post-COVID employee engagement and talent development • CereLink ICP Monitor – Full year impact in the U.S. and Europe with Japan launch in Q2 • St

  18. Slide 18: Long-Term Financial Targets

    Long-Term Financial Targets Long-Term Target Organic Growth 5% – 7% Key Actions and Enablers • Substantially Completed Portfolio Transformation Adj. EPS Growth Double-Digit • Consistent Operational and Commercial Execution Adj. Gross Margin 70% – 72% • Emphasis on Growth Initiatives: Innovation and

  19. Slide 19: Appendix: Non-GAAP Reconciliations

    Appendix Non-GAAP Reconciliations

  20. Slide 20: Fourth Quarter and FY 2021 Financial Results

    Fourth Quarter and FY 2021 Financial Results % of Revenues Q4 2021 Q4 2020 Change FY 2021 FY 2020 Change Total Revenues $405.5 $388.6 4.3% $1,542.4 $1,371.9 12.4% Gross Margin 61.5% 62.2% -70BPS 61.2% 62.0% -80BPS Adj. Gross Margin(1) 66.8% 68.2% -140BPS 67.7% 68.0% -30BPS Net Income $45.4 $92.7 (51

  21. Slide 21: Fourth Quarter and FY 2021 Organic Growth Reconciliation

    Fourth Quarter and FY 2021 Organic Growth Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 Neurosurgery $211.9 $200.3 $803.0 $716.3 Instruments $58.8 $54.0 $222.3 $178.5 Total Codman Specialty Surgical $270.7 $254.3 $1,025.2 $894.8 Wound Reconstr

  22. Slide 22: Fourth Quarter and FY 2021 Adjusted EBITDA Margin Reconciliation

    Fourth Quarter and FY 2021 Adjusted EBITDA Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 GAAP Net Income $45.4 $92.7 $169.1 $133.9 Depreciation 10.4 10.2 39.2 41.1 Intangible asset amortization 20.3 15.9 83.4 74.5 Other (income), net (3

  23. Slide 23: Fourth Quarter and FY 2021 Adjusted EPS Reconciliation

    Fourth Quarter and FY 2021 Adjusted EPS Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 GAAP Net Income $45.4 $92.7 $169.1 $133.9 COVID-19 related charges 0.0 (0.2) 0.0 3.5 Convertible debt non-cash interest(1) - 4.3 - 15.4 Expenses related to d

  24. Slide 24: Fourth Quarter and FY 2021 Adjusted Free Cash Flow Reconciliation

    Fourth Quarter and FY 2021 Adjusted Free Cash Flow Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 Net Cash from Operating Activities $69.3 $80.3 $312.4 $203.8 Purchases of Property and Equipment ($27.4) ($8.4) ($48.0) ($38.9) Free Cash Flow $41

  25. Slide 25: Fourth Quarter and FY 2021 Gross Margin Reconciliation

    Fourth Quarter and FY 2021 Gross Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 Reported Gross Profit $249.3 $241.6 $944.6 $851.0 COVID-19 related charges - (0.0) (0.0) 3.8 Structural optimization charges 2.6 6.0 8.8 8.3 Acquisition, div

  26. Slide 26: Fourth Quarter and FY 2021 Adjusted SG&A Reconciliation

    Fourth Quarter and FY 2021 Adjusted SG&A Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2021 Q4 2020 FY 2021 FY 2020 Reported SG&A $162.3 $162.4 $637.4 $594.5 COVID-19 related charges 0.0 (0.2) 0.0 (0.3) Structural optimization charges 2.6 (0.3) 7.8 6.2 Acquisition, divest

Integra LifeSciences Holdings — FY2021 Earnings Presentation on 6ix